The perils of Alzheimer's drug development
- PMID: 19199878
- PMCID: PMC2747724
- DOI: 10.2174/156720509787313871
The perils of Alzheimer's drug development
Comment in
-
Resurrecting clinical pharmacology as a context for Alzheimer disease drug development.Curr Alzheimer Res. 2009 Feb;6(1):79-81. doi: 10.2174/156720509787313916. Curr Alzheimer Res. 2009. PMID: 19199879 Free PMC article. Review.
Comment on
-
Alzheimer's disease drug development in 2008 and beyond: problems and opportunities.Curr Alzheimer Res. 2008 Aug;5(4):346-57. doi: 10.2174/156720508785132299. Curr Alzheimer Res. 2008. PMID: 18690832 Free PMC article. Review.
References
-
- Altstiel LD. Barriers to Alzheimer's disease drug discovery and development in the biotechnology industry. Alzheimer's Disease and Associated Disorders. 2002;(Supp 1):S29–S32. - PubMed
-
- Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology. 1998;50(3):669–77. - PubMed
-
- Kadir A, Andreasen N, Almkvist O, Wall A, Forsberg A, Engler H, Hagman G, Lärksäter M, Winblad B, Zetterberg H, Blennow K, Långström B, Nordberg A. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol. 2008 May;63(5):621–31. - PubMed
